Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln

Reuters

11/12

Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln

Overview

BeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last year
Plinabulin shows promising results in NSCLC patients at SITC 2025 presentations
SEED secures $30 mln financing, achieves IND clearance for RBM39 program

Outlook

BeyondSpring emphasizes Plinabulin's potential in resensitizing tumors resistant to checkpoint inhibitors
Company highlights SEED's IND clearance for RBM39 degrader program in the US and China
BeyondSpring focuses on advancing Plinabulin's clinical development for durable survival benefits

Result Drivers

Research and development (R&D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$1.70 mln

Press Release: ID:nGNX29qBv7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582758003"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582758003\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582758003?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582758003","market":"nz","top_or_hot":-1,"title":"Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln</title></head><body><p><span>Overview</span></p><ul><li><p>BeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last year</p></li><li><p>Plinabulin shows promising results in NSCLC patients at SITC 2025 presentations</p></li><li><p>SEED secures $30 mln financing, achieves IND clearance for RBM39 program</p></li></ul><p><span>Outlook</span></p><ul><li><p>BeyondSpring emphasizes Plinabulin's potential in resensitizing tumors resistant to checkpoint inhibitors</p></li><li><p>Company highlights SEED's IND clearance for RBM39 degrader program in the US and China</p></li><li><p>BeyondSpring focuses on advancing Plinabulin's clinical development for durable survival benefits</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development (R&amp;D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.70 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX29qBv7</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-12 20:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln</title></head><body><p><span>Overview</span></p><ul><li><p>BeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last year</p></li><li><p>Plinabulin shows promising results in NSCLC patients at SITC 2025 presentations</p></li><li><p>SEED secures $30 mln financing, achieves IND clearance for RBM39 program</p></li></ul><p><span>Outlook</span></p><ul><li><p>BeyondSpring emphasizes Plinabulin's potential in resensitizing tumors resistant to checkpoint inhibitors</p></li><li><p>Company highlights SEED's IND clearance for RBM39 degrader program in the US and China</p></li><li><p>BeyondSpring focuses on advancing Plinabulin's clinical development for durable survival benefits</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development (R&amp;D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.70 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX29qBv7</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BYSI","symbol_name":"萬春藥業","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0D2:1","article_id":"2582758003","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582758003","pubTimestamp":1762949330,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mlnOverviewBeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last yearPlinabulin shows promising results in NSCLC patients at SITC 2025 pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BYSI":"万春药业","BK4139":"生物科技"},"translate_title":"制药商BeyondSpring第三季度净亏损收窄至170万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BYSI":0.9},"content_text":"Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mlnOverviewBeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last yearPlinabulin shows promising results in NSCLC patients at SITC 2025 presentationsSEED secures $30 mln financing, achieves IND clearance for RBM39 programOutlookBeyondSpring emphasizes Plinabulin's potential in resensitizing tumors resistant to checkpoint inhibitorsCompany highlights SEED's IND clearance for RBM39 degrader program in the US and ChinaBeyondSpring focuses on advancing Plinabulin's clinical development for durable survival benefitsResult DriversResearch and development (R&D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$1.70 mlnPress Release: ID:nGNX29qBv7For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}